Acam2000 Market Report 2026

Acam2000 Market Overview

• The Acam2000 market growth in the historic period has been driven by smallpox eradication programs, biodefense initiatives • Market expansion is supported by renewed mpox outbreaks, increased biodefense funding • Growth Driver: Growing Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Increasing Demand For Immunization And Outbreak Preparedness • Market Trend: Regulatory Progress In Expanding Vaccine Indications For Mpox Prevention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acam2000 Market?

ACAM2000 is a live vaccinia virus vaccine approved by the Food and Drug Administration for immunization against smallpox. It is primarily used for individuals at high risk of exposure, such as military personnel and laboratory workers handling orthopoxviruses. ACAM2000 stimulates immunity by introducing a weakened virus similar to smallpox, helping the body build defense against the disease. The main indications of acam2000 are smallpox and mpox. Smallpox is a viral disease caused by the variola virus, eradicated globally through vaccination programs but still a concern for bioterrorism. Vaccines such as acam2000 are used for immunization in high-risk individuals to ensure preparedness against potential outbreaks. It is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. The end users include adults and the geriatric population.

What Is The Acam2000 Market Growth Forecast?

The growth in the forecast period can be attributed to renewed mpox outbreaks, increased biodefense funding, global health security focus, expansion of emergency stockpiles, government procurement programs. Major trends in the forecast period include strategic stockpiling of smallpox vaccines, preparedness for emerging orthopox threats, government controlled vaccine distribution, focus on high risk population immunization, national biosecurity programs.

Global Acam2000 Market Segmentation

1) By Indication: Smallpox, Mpox 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adults, Geriatric Population

What Are The Drivers Of The Acam2000 Market?

The growing prevalence of infectious diseases is expected to propel the growth of the acam2000 market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms, such as bacteria, viruses, fungi, or parasites, that can be transmitted directly or indirectly from one individual to another. The rate of infectious disease incidence is rising due to increased travel, which facilitates the rapid spread of pathogens across borders. ACAM2000 supports infectious disease management by providing immunization against smallpox and mpox, reducing the risk of outbreaks and enhancing public health preparedness. It helps healthcare systems and governments mitigate the impact of potential bioterrorism threats and naturally occurring infections, ensuring rapid protection for high-risk populations and strategic stockpiles. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the growing prevalence of infectious diseases is driving the growth of the acam2000 industry. The rising healthcare expenditure is expected to propel the growth of the acam2000 market going forward. Healthcare expenditure refers to the total amount spent on healthcare goods and services, including personal health care, preventive services, and public health activities to improve health outcomes within a specific period. Healthcare expenditure is rising due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure is utilized for ACAM2000 through funding for vaccine procurement, stockpiling, distribution, and administration as part of biodefense and public health preparedness programs. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the rising healthcare expenditure is driving the growth of the acam2000 industry.

Key Players In The Global Acam2000 Market

Major companies operating in the acam2000 market are Emergent BioSolutions Inc.

Global Acam2000 Market Trends and Insights

Major companies operating in the acam2000 market are focusing on advancing their vaccine portfolios, such as developing next-generation formulations, to enhance accessibility, improve safety profiles, and address public health threats. Next-generation vaccine formulations refer to updated versions of existing vaccines that may offer benefits like longer shelf life, reduced dosage volumes, or refined manufacturing processes. For instance, in August 2024, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received a US Food and Drug Administration (FDA) approval for the supplemental Biologics License Application (sBLA) for ACAM2000 (Smallpox and Mpox [Vaccinia] Vaccine, Live) seeks to expand its indication to include prevention of pox in individuals at high risk of infection. The approval is supported by prior human safety data and evidence from a controlled animal study demonstrating the vaccine's effectiveness in protecting against mpox virus exposure.

Regional Insights

North America was the largest region in the acam2000 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Acam2000 Market?

The acam2000 market consists of sales of diluent for reconstitution, bifurcated needles, sterile syringes, and emergency use authorization documentation. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acam2000 Market Report 2026?

The acam2000 market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acam2000 industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.